InNexus Biotechnology, Inc.

TSX.V: IXS, OTCBB: IXSBF 


VANCOUVER, Feb. 14  /PRNewswire-FirstCall/ -- InNexus Biotechnology, Inc. is pleased to announce that Dr. Charles Morgan has been invited to speak at the BIO CEO & Investor Conference, Waldorf Astoria Hotel, New York. Dr. Morgan's presentation will take place in the Duke of Windsor Room at 1:30 PM. on February 15th.

This presentation will be available on the companies web site: http://www.innexusbiotech.com/

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products.

About InNexus

InNexus is an innovative antibody-driven drug development company that has developed two technology platforms, SuperAntibody(TM) and TransMAbs(TM), which improve the potency of existing antibody products while opening new markets and disease applications. Both platforms utilize unique, novel and patented methods and technologies of InNexus. InNexus is headquartered in British Columbia, Canada and has its own in-house developmental facilities. These development facilities provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus please visit http://www.innexusbiotech.com/.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not historical facts and are subject to risks and uncertainties which could cause actual results and the timing of certain events to differ materially from those set forth in or implied herein including, without limitation, risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims litigation and other risks associated with the Company's proposed activities.

  On behalf of the Board of Directors of InNexus Biotechnology, Inc.

  Dr. A. Charles Morgan
  President


  To contact us:

  Telephone: [phone]
  Fax: [phone]
  Email: 

  Investor Relations:
  Telephone: [phone] or 1-888-271-0788
  Email: 


  The TSX Venture Exchange has neither approved nor disapproved of the
                      information contained herein.


DATASOURCE: InNexus Biotechnology, Inc.



CONTACT: Telephone: [phone], Fax: [phone],

Email: ; Investor Relations: Telephone:

[phone] or 1-888-271-0788, Email: 

Copyright